title: Idiotype vaccination strategies against a murine B-cell lymphoma: dendritic cells loaded with idiotype and bispecific idiotype x anti-class II antibodies can protect against tumor growth.
abstract: Three strategies were used to evaluate 38C13 B-cell lymphoma-specific idiotype immunization to protect against subsequent lymphoma challenge in C3H/He mice. It was observed that tumor-specific immunity could be induced by immunization with (i) KLH-conjugated 38C13 B-cell lymphoma idiotype in complete Freund's adjuvants (survival rate 80%), (ii) dendritic cells pulsed in vitro with native idiotype protein (survival rate 80%), and (iii) bispecific antibodies composed of B-lymphoma-related idiotype and an MHC class II binding moiety (survival rate 40%). Presentation of idiotype determinants by dendritic cells or bispecific antibody resulted in lymphoma-specific immunity and obviated the requirement for carrier protein or adjuvant. Moreover, primed dendritic cells induced predominant development of a tumor-specific T-cell response. Each of these immunization strategies resulted in long-term survival without the emergence of idiotype variants or the induction of tumor dormancy.
authors.affiliation: Klinik I für Innere Medizin, Universität zu Köln, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Bohlen
authors.forename: K
authors.initials: K
authors.lastname: Thielemanns
authors.forename: H
authors.initials: H
authors.lastname: Tesch
authors.forename: A
authors.initials: A
authors.lastname: Engert
authors.forename: H J
authors.initials: HJ
authors.lastname: Wolf
authors.forename: B
authors.initials: B
authors.lastname: van Camp
authors.forename: J
authors.initials: J
authors.lastname: Urbain
authors.forename: V
authors.initials: V
authors.lastname: Diehl
mesh_terms: D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D018033:Antibodies, Bispecific / Q000627:therapeutic use*; D000917:Antibody Formation; D002478:Cells, Cultured; D003713:Dendritic Cells / Q000276:immunology* / Q000637:transplantation*; D000949:Histocompatibility Antigens Class II / Q000276:immunology*; D007111:Immunity, Cellular; D007075:Immunoglobulin M / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods*; D008213:Lymphocyte Activation; D016393:Lymphoma, B-Cell / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D018365:Neoplasm, Residual / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D000888:Antibodies, Anti-Idiotypic; D018033:Antibodies, Bispecific; D000949:Histocompatibility Antigens Class II; D007075:Immunoglobulin M